RXRX Stock Overview
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery.
Recursion Pharmaceuticals, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$9.26|
|52 Week High||US$21.19|
|52 Week Low||US$4.92|
|1 Month Change||-16.50%|
|3 Month Change||-9.22%|
|1 Year Change||-51.03%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-70.42%|
Recent News & Updates
Companies Like Recursion Pharmaceuticals (NASDAQ:RXRX) Can Afford To Invest In GrowthJul 25
These Analysts Think Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) Sales Are Under ThreatMay 16
Recursion Pharmaceuticals, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting NowMay 14
Recursion Pharmaceuticals (NASDAQ:RXRX) Is In A Good Position To Deliver On Growth PlansApr 07
|RXRX||US Biotechs||US Market|
Return vs Industry: RXRX underperformed the US Biotechs industry which returned -14.4% over the past year.
Return vs Market: RXRX underperformed the US Market which returned -18.5% over the past year.
|RXRX Average Weekly Movement||12.3%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.6%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: RXRX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: RXRX's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer.
Recursion Pharmaceuticals, Inc. Fundamentals Summary
|RXRX fundamental statistics|
Is RXRX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|RXRX income statement (TTM)|
|Cost of Revenue||US$197.44m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.30|
|Net Profit Margin||-860.34%|
How did RXRX perform over the long term?See historical performance and comparison